EVAg

Lyophilized encapsidated RNA for SARS-CoV-2 real time RT-PCR targeting region of the N(CUB) gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by Charité (CUB) Berlin. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized encapsidated RNA for SARS-CoV-2 real time RT-PCR targeting region of the RdRp (IP2/IP4) gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by Institut Pasteur Paris. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized encapsidated RNA for 2019-nCoV real time RT-PCR targeting region of the E gene (for 200 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (2400 rxns in the form of 100x24 rnxs). Target, primers and probe designed by CUB Berlin. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized encapsidated RNA for 2019-nCoV real time RT-PCR targeting region of the E gene (for 100 Rxns); AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (960 rxns in the form of 40x24 rnxs). Target, primers and probe designed by CUB Berlin. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized encapsidated RNA for 2019-nCoV real time RT-PCR targeting region of the E gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by CUB Berlin. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) as of Jan 30, 2020, available from https://www.mdpi.com/1999-4915/12/2/159/pdf. Primers and Probe sequences designed by Charité Universitätsmedizin Berlin ; https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) in the RdRp (IP4) gene. Primers and Probe sequences designed by Institut Pasteur: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2) SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) in the N (CUB) gene. Primers and Probe sequences designed by Charité Universitätsmedizin Berlin; https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf). SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S1 domain of SARS-CoV-2 Spike as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S1 domain of SARS-CoV-2 Spike domain of the wild type strain, as determined by ELISA.

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike as determined by ELISA

Human monoclonal recombinant IgG1 targeting the S2 domain of SARS-CoV-2 Spike domain of the wild type strain, as determined by ELISA.

Infectious cell culture supernatant containing SARS-CoV-2 (hCoV-19/Netherlands/NH-EMC-1720/2021, Omicron variant, lineage B.1.1.529.

SARS-CoV-2 virus, strain UVE/SARS-CoV-2/2021/FR/X1 (Lineage B 1.617.2, Delta) France 2021, complete genome sequence. Absence of spike mutation in A222

Vial containing RNA of SARS-CoV-2 (hCoV-19/Netherlands/NH-EMC-1720/2021, Omicron variant, lineage B.1.1.529. This strain has been cultivated on Calu-3 cells. . GSAID reference: hCoV-19/Netherlands/NH-RIVM-71084/2021.

Freeze-dried SARS-CoV-2 virus, strain SARS-CoV-2/2021/FR/0610 (Lineage B 1.617.2, Delta) France 2021, complete genome sequence. Presence of spike mutation A222V and absence of spike mutation Y145H.

Infectious cell culture supernatant of SARS-CoV-2 from The Netherlands

Freeze-dried SARS-CoV-2 virus, strain UVE/SARS-CoV-2/2020/FR/702, France 2020, complete genome sequence. NB: this virus contains the G614 european mutation in the spike sequence

Panel of Freeze-dried SARS-CoV-2 variants (Europe, UK, South Africa, Brazil, Delta). Please note Brazilian variant can not be supplied to private entities

RNA extracted from infected cell culture supernatant containing SARS-CoV-2 (strain hCoV-19/Aruba_11401/2021, California variant, nextstrain clade CAL.20C, lineage B.1.429).

RNA extracted from infected cell culture supernatant containing SARS-CoV-2 strain hCoV-19/Netherlands/Gelderland_20949/2021, N501T (S), nextstrain clade 20D, lineage C.2.

RNA extracted from infected cell culture supernatant containing SARS-CoV-2 strain hCoV-19/Netherlands/NoordBrabant_10706/2021, Brazilian variant P.2, nextstrain clade 20B, lineage B.1.1.28 P.2.

RNA extracted from infected cell culture supernatant containing SARS-CoV-2 strain hCoV-19/Netherlands/NoordHolland_10915/2021, Brazilian variant P.1, nextstrain clade 20J, lineage B.1.1.28 P.1.

RNA extracted from infected cell culture supernatant containing SARS-CoV-2 strain hCoV-19/Netherlands/NoordHolland_10159/2021, South African variant, nextstrain clade 20H, lineage B.1.351).